

Type 2 Diabetes - Pipeline Review, H1 2020

<https://marketpublishers.com/r/T85A45F306FEN.html>

Date: May 2020

Pages: 1220

Price: US\$ 2,500.00 (Single User License)

ID: T85A45F306FEN

Abstracts

Type 2 Diabetes - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Type 2 Diabetes – Pipeline Review, H1 2020, provides an overview of the Type 2 Diabetes (Metabolic Disorders) pipeline landscape.

Type 2 diabetes is a chronic condition and is the most common form of diabetes. High levels of glucose are a characteristic feature. The body might become resistant to insulin or may not produce enough amounts. Due to abnormal insulin functioning, glucose is concentrated in the blood leading to elevated levels and hence causing type 2 diabetes. Symptoms include fatigue, weight issues, vision deficits and various other effects. Risk factors include family history, age, obesity, physical inactivity and high blood pressure. This condition is handled by lifestyle alterations and regular medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Type 2 Diabetes – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Type 2 Diabetes (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Type 2 Diabetes (Metabolic Disorders) pipeline guide also reviews of key players

involved in therapeutic development for Type 2 Diabetes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 15, 1, 40, 67, 78, 3, 5, 223, 43 and 8 respectively. Similarly, the Universities portfolio in Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 2, 1, 59 and 19 molecules, respectively.

Type 2 Diabetes (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Type 2 Diabetes (Metabolic Disorders).

The pipeline guide reviews pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Type 2 Diabetes (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Type 2 Diabetes (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Type 2 Diabetes (Metabolic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Type 2 Diabetes (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Type 2 Diabetes - Overview

Type 2 Diabetes - Therapeutics Development

Type 2 Diabetes - Therapeutics Assessment

Type 2 Diabetes - Companies Involved in Therapeutics Development

Type 2 Diabetes - Drug Profiles

Type 2 Diabetes - Dormant Projects

Type 2 Diabetes - Discontinued Products

Type 2 Diabetes - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Type 2 Diabetes, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Type 2 Diabetes - Pipeline by 3SBio Inc, H1 2020
Type 2 Diabetes - Pipeline by Adare Pharmaceuticals Inc, H1 2020
Type 2 Diabetes - Pipeline by ADM Therapeutics, H1 2020
Type 2 Diabetes - Pipeline by Adocia SAS, H1 2020
Type 2 Diabetes - Pipeline by Aerami Therapeutics, H1 2020
Type 2 Diabetes - Dormant Projects, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Type 2 Diabetes, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

3SBio Inc
Adare Pharmaceuticals Inc
ADM Therapeutics
Adocia SAS
Aerami Therapeutics
Afimmune Biopharma Ltd
AgeX Therapeutics Inc
Akeru Therapeutics Inc
Akston Biosciences Corp
Algiac Pharmaceuticals GmbH
Alms Therapeutics
AlphaMab Co Ltd
Amgen Inc
AmideBio LLC
Anji Pharmaceuticals Inc
AnyGen Co Ltd
Apcegen Technologies Pvt Ltd
Aphios Corp
Apoglyx AB
APT Therapeutics Inc
Aptamer Sciences Inc

AptamiR Therapeutics Inc
Arena Pharmaceuticals Inc
Aridad Therapeutics SL
Arkay Therapeutics LLC
Artery Therapeutics Inc
AsiaBiome
Astellas Pharma Inc
AstraZeneca Plc
Atrogi AB
Auritec Pharmaceuticals Inc
Avolynt Inc
Beijing Eastern Biotech Co Ltd
Betagenon AB
Betta Pharmaceuticals Co Ltd
Biocon Ltd
BioEos Ltd
Biogenomics Ltd
BioKier Inc
BioLingus AG
BioRestorative Therapies Inc
Biozeus Pharmaceutical SA
Boehringer Ingelheim International GmbH
Boryung Pharmaceutical Co Ltd
Boston Therapeutics Inc
Braasch Biotech LLC
BrightGene Bio-Medical Technology Co Ltd
Buto Biopharma Inc
C4X Discovery Holdings Plc
Cadila Healthcare Ltd
Cadila Pharmaceuticals Ltd
Caelus Health
Caldan Therapeutics Ltd
CAR-T (Shanghai) Biotechnology Co Ltd
Carlina Technologies SAS
Carmot Therapeutics Inc
Cellix Bio Pvt Ltd
Celon Pharma SA
Centaurus Therapeutics Inc
Center Laboratories Inc

CGeneTech (Suzhou China) Co Ltd
Chain Biotechnology Ltd
Chengdu Di'ao Pharmaceutical Group Co Ltd
Chengdu Easton Biopharmaceuticals Co Ltd
Chipscreen Biosciences Ltd
Chong Kun Dang Pharmaceutical Corp
Chongqing Chenan BioPharm Co Ltd
Chongqing Conquer Pharmaceutical Co Ltd
Chugai Pharmaceutical Co Ltd
Cinnagen Co
CJ HealthCare Corp
CohBar Inc
Coherus BioSciences Inc
Concenter BioPharma Silkim Ltd
Corbus Pharmaceuticals Inc
CRISPR Therapeutics AG
Cryno LLC
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co Ltd
D&D Pharmatech Co Ltd
Daewoong Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Delpor Inc
Diabetology (Products) Ltd
Diamyd Medical AB
Diapin Therapeutics LLC
Diasome Pharmaceuticals Inc
DiscoveryBiomed Inc
DNJ Pharma Inc
DNX Biopharmaceuticals Inc
Dong-A Socio Holdings Co Ltd
EastGate Pharmaceuticals Inc
Elevian Inc
Eli Lilly and Co
Emerald Organic Products Inc
Emmaus Life Sciences Inc
Empros Pharma AB
EncuraGen Inc
Endece LLC
Energenesi Biomedical Co Ltd

Enesi Pharma Ltd
Enteris BioPharma Inc
Enzene Biosciences Ltd
Enzo Biochem Inc
Eternygen GmbH
Evotec SE
F. Hoffmann-La Roche Ltd
Fairbanks Pharmaceuticals Inc
Fochon Pharma Inc
Forkhead BioTherapeutics Inc
FortuneRock (China) Ltd
Gan & Lee Pharmaceutical Ltd
Generex Biotechnology Corp
Genexine Inc
Genovate Biotechnology Co LTD
Genprex Inc
Geropharm
Gilead Sciences Inc
GL Pharm Tech Corp
Glaceum Inc
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd
Glucox Biotech AB
Gmax Biopharm Ltd
Guangdong Zhongsheng Pharmaceutical Co Ltd
Gubra ApS
Handok Inc
Hangzhou East China Pharmaceutical Group Co Ltd
Hangzhou Jiuyuan Gene Engineering Co Ltd
Hanmi Pharmaceuticals Co Ltd
HEC Pharm Co Ltd
Hefei Industrial Pharmaceutical Institute Co Ltd
Hengrui Therapeutics Inc
Housey Pharmaceutical Research Laboratories LLC
HSRx Group
Hua Medicine Shanghai Ltd
Huons Co Ltd
Hyundai Pharma Co Ltd
Ildong Pharmaceutical Co Ltd

Immupharma Plc
Immuron Ltd
Impetis Biosciences Ltd
Inflammasome Therapeutics Inc
Inflazome Ltd
Innovimmune Biotherapeutics Inc
Inspyr Therapeutics Inc
InStar Technologies AS
Intarcia Therapeutics Inc
Integral Molecular Inc
Ionis Pharmaceuticals Inc
Japan Tobacco Inc
Jeil Pharmaceutical Co Ltd
Jiangsu Chia-tai Tianqing Pharmaceutical Co Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu T-mab BioPharma Co Ltd
Johnson & Johnson
Jortan Pharmaceuticals Inc
Kadimastem Ltd
Kaneq Bioscience Ltd
KB Biomed Inc
Kissei Pharmaceutical Co Ltd
Klotho Therapeutics Inc
Kowa Co Ltd
Kriya Therapeutics
Laboratorios Silanes SA de CV
Lannett Co Inc
Lead Discovery Center GmbH
Leading BioSciences Inc
Lexicon Pharmaceuticals Inc
LG Chem Ltd
Lin Bioscience Inc
LipimetiX Development Inc
Lixte Biotechnology Holdings Inc
Longevity Biotech Inc
Lotus Pharmaceutical Co Ltd
Luye Pharma Group Ltd
Lyndra Inc

MannKind Corp
MD Healthcare Inc
Medesis Pharma SA
Medlab Clinical Ltd
Melior Pharmaceuticals I Inc
Merck & Co Inc
Mesoblast Ltd
Metabolic Solutions Development Company LLC
Metabolys SAS
Metacrine Inc
Metavant Sciences Ltd
MetrioPharm AG
Metynex Pharmaceuticals AB
Mito BioPharm LLC
Mitsubishi Tanabe Pharma Corp
Moogene Medi Inc
Naia Ltd
Neuraly Inc
Neurimmune Holding AG
Neurodon LLC
NGM Biopharmaceuticals Inc
Novartis AG
NovaTarg Therapeutics Inc
NovMetaPharma Co Ltd
Novo Nordisk AS
NuSirt Biopharma Inc
NutriBand Inc
Oblique Therapeutics AB
OliPass Corporation
Omeros Corp
OPKO Health Inc
OptiKira LLC
Oramed Pharmaceuticals Inc
Orbsen Therapeutics Ltd
Original BioMedicals Co Ltd
Palatin Technologies Inc
Panorama Research Inc
Paras Biopharmaceuticals Finland Oy
Park Active Molecules

PegBio Co Ltd
Peptron Inc
Pfizer Inc
PharmaCyte Biotech Inc
Pila Pharma AB
Polus Inc
Poxel SA
Precigen Inc
Preveceutical Medical Inc
ProLynx LLC
Prometheon Pharma LLC
Protheragen Inc
Prous Institute for Biomedical Research SA
Purzer Pharmaceutical Co Ltd
QuiaPEG Pharmaceuticals AB
Remd Biotherapeutics Inc
reMYND NV
Reneo Pharmaceuticals Inc
Renova Therapeutics Inc
Rezolute Inc
Rhythm Pharmaceuticals Inc
Ridgeline Therapeutics LLC
Samjin Pharm Co Ltd
Saniona AB
Sanofi
Sanwa Kagaku Kenkyusho Co Ltd
SatRx
SBI Pharmaceuticals Co Ltd
ScandiCure AB
Schrodinger LLC
Sciwind Biosciences Co Ltd
Scohia Pharma Inc
Senseion Inc
Sensulin LLC
Seres Therapeutics Inc
Serodus ASA
Serometrix LLC
Serpina Pharma LLC
Shandong Luye Pharmaceutical Co Ltd

Shanghai Fosun Pharmaceutical (Group) Co Ltd
Shanghai Innogen Pharmaceutical Technology Co Ltd
Shanghai Yingli Pharmaceutical Co Ltd
Shenzhen HighTide Biopharmaceutical Ltd
Shionogi & Co Ltd
Shouyao Holding Co Ltd
Sichuan Haisco Pharmaceutical Co Ltd
Signal Pharma Ltd
Sihuan Pharmaceutical Holdings Group Ltd
Sino Biopharmaceutical Ltd
Sirona Biochem Corp
SJT Molecular Research SL
Sosei Heptares
Stelis Biopharma Pvt Ltd
Sulfateq BV
Suzhou Ribo Life Sciences Co Ltd
Suzuken Co Ltd
Sveikatal Inc
SymbioCellTech LLC
Taisho Pharmaceutical Holdings Co Ltd
Takeda Pharmaceutical Co Ltd
Techfields Pharma Co Ltd
Teijin Pharma Ltd
Theracos Inc
Thermalin Inc
TiumBio Co Ltd
Tonghua Dongbao Pharmaceutical Co Ltd
Torrent Pharmaceuticals Ltd
Transgene Biotek Ltd
Transira Therapeutics LLC
TTY Biopharm Co Ltd
TWi Biotechnology Inc
Twoxar Inc
Uni-Bio Science Group Ltd
United Biomedical Inc
USV Pvt Ltd
Valin Technologies Ltd
ViaCyte Inc
Viking Therapeutics Inc

VitNovo Inc
Vivus Inc
vTv Therapeutics Inc
Vybion Inc
Wuxi Hebang Biotechnology Co Ltd
XERIS Pharmaceuticals Inc
XL-protein GmbH
XOMA Corp
XuanZhu Pharma Co Ltd
Yichang Hec Changjiang Pharmaceutical Co Ltd
Youngene Therapeutics Co Ltd
Yuhan Corp
Zealand Pharma AS
Zhejiang Doer Biologics Corp
Zhejiang Hisun Pharmaceutical Co Ltd
Zhejiang Huayang Pharmaceutical Co Ltd
Zih Yuan Tang Biotechnology Co Ltd

I would like to order

Product name: Type 2 Diabetes - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/T85A45F306FEN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T85A45F306FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970